1. Scrip
  2. >>Business
  3. >>Earnings

Incyte Points To Niktimvo, Three Near-Term Approvals For Growth

 
• By Joseph Haas

With Jakafi slated to lose US patent protection in 2028, Incyte is looking to GVHD launch product Niktimvo and label expansions for Opzelura, Monjuvi and Zynyz to drive late-decade growth.

Incyte points to pending approvals, Phase III readouts and initiations as potential growth drivers (Shutterstock)

As the loss of exclusivity for Incyte’s top-seller Jakafi (ruxolitinib) looms in 2028, the firm is making the case that other opportunities will deliver growth for the rest of the decade. Recently launched Niktimvo (axatilimab) and label expansions for Opzelura (ruxolitinib cream), Monjuvi (tafasitinib) and Zynyz (retifanlimab) will collectively generate an additional $1bn in revenue for the company by 2029, CEO Herve Hoppenot predicted during the firm’s fourth-quarter and full-year 2024 earnings call on 10 February, and there are more opportunities advancing through the pipeline.

Key Takeaways
  • Incyte reported Q4 and full-year sales growth led by Jakafi and Opzelura, but put emphasis on a recent launch and expected approvals and pivotal readouts.

Each of those products or new indications should reach the market before the end of 2025, the exec added, with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By Andy Smith

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

 
• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

More from Anticancer

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.